[1] Lu Mushun, Liu Jiao, Liu Tianfu, et al. A Clinical research on the treatment of Prenatal Chronic Hepatitis B by Yungan Prescription [J]. Modern Traditional Chinese Medicine, 2020, (03): 92-94. [doi: 10.13424/j.cnki.mtcm.2020.03.025]
A Clinical research on the treatment of Prenatal Chronic Hepatitis B by Yungan Prescription
- Article number:
- 1672-0571(2020)03-0092-03
- Keywords:
- Prenatal Chronic Hepatitis B; pregnancy; Yungan Prescription; hepatic function; Ornithine Aspartate
- ZTFLH:
- R512.6+2
- Code:
- A
- Abstract:
- Objective To observe the clinical effect of treating Prenatal Chronic Hepatitis by Yungan( liver in pregnancy) Prescription in terms of anti - virus and liver protection. Method The 32cases in treatment group are given Yungan Prescription therapy, and another 32 cases in control group are treated by means of oral administration of Ornithine Aspartate Granules for a period of 12 weeks. The hepatic functional indexes and overall effective rate are compared between two groups before and after treatment, including the ALT, AST, and TBiL. Meanwhile, the improvement time of the digestive system symptoms is observed. Result After 12 weeks, the ALT, AST, and TBiL are slightly reduced by contrast with the indexes before treatment, and the difference is of statistical significance( P <0. 01) . The ALT, AST, and TBiL in treatment group are lower than the control group , and the difference is of statistical significance( P <0. 05) . The overall effective rate in treatment group is 87. 5%, control group 56. 6%, thus the difference is of statistical significance( P <0.05) . The improvement time of abdominal distention, poor appetite, vomiting are shorter than that of control group, and the difference is of statistical significance( P <0. 01) . The difference is of statistical significance by contrast with the adverse effect in two groups. Conclusion Yungan Prescription is effective and secure in the treatment of Prenatal Chronic Hepatitis B.
References:
[1]中华医学会肝病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].中华肝脏病杂志,2015,23(12):888-905.
[2]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国科技出版社,2002:145-148
[3]李飞凤,黄启涛.慢性乙型肝炎孕妇 HBeAg阳性与不良妊娠结局关系研究[J].中国实用妇科与产科杂志,2016,32(7):680-684.
[4]陈红燕,李秀,彭松绪,等.慢性乙型肝炎及 HBeAg状态对母婴结局的影响研究[J].中华疾病控制杂志,2018,22(6):617-620.
[5]Cheng Q,Zhao B,Huang Z, et al. Epigenome – wide study for the offspring exposed to maternal HBV infection during pregnancy, a pilot study[ J] . Gene, 2018, 658:76-85.
[6]段玉红,苏虹霞,杨红莲.基于组分配伍探讨黄连?黄芩保肝的物质基础[J].中国现代中药,2018,20(12): 1483-1488.
[7]王涵,杨娜,谭静,等.白术化学成分?药理作用及临床应用的研究进展[J].甘肃医药,2018,37(1):23-26.
[8]张晓娟,左冬冬.白术化学成分及药理作用研究新进展[J].中医药信息,2018,35(6):101-106.
[9]张嫦丽,张可锋,许有瑞,等.黄花倒水莲的化学成分与药理活性研究进展[J].中国药房,2017,28(19):2724 -2728.
[10]游昕,熊大国,郭志斌,等.茯苓多种化学成分及药理作用的研究进展[J].安徽农业科学,2015,43(2):106-109.
Memo
基金项目:广州市花都区科技计划项目[花科工信字(2017)38号]